Evogene Ltd. Files 20-F Annual Report for Fiscal Year Ended December 31, 2023

TL;DR

<b>Evogene Ltd. filed its 20-F annual report for the fiscal year ended December 31, 2023, detailing its business operations and financial standing.</b>

AI Summary

Evogene Ltd. (EVGN) filed a Foreign Annual Report (20-F) with the SEC on March 28, 2024. Evogene Ltd. filed its 20-F annual report for the fiscal year ending December 31, 2023. The report covers the period from January 1, 2023, to December 31, 2023. The company's principal executive offices are located at 13 Gad Feinstein Street, Park Rehovot, Rehovot, Israel. Evogene Ltd. is classified under the SIC code 2870 for Agriculture Chemicals. The filing indicates that potential ordinary shares were not considered for diluted loss per share due to their anti-dilutive effect.

Why It Matters

For investors and stakeholders tracking Evogene Ltd., this filing contains several important signals. This filing provides investors with a comprehensive overview of Evogene's performance and strategic direction for the past fiscal year. The inclusion of details on potential ordinary shares and their anti-dilutive effect offers insight into the company's share structure and earnings per share calculations.

Risk Assessment

Risk Level: low — Evogene Ltd. shows low risk based on this filing. The filing is a standard annual report (20-F) and does not contain new material events or significant financial disclosures that would indicate elevated risk.

Analyst Insight

Review the full 20-F filing for detailed financial statements, risk factors, and management discussion to understand Evogene's current business position and future outlook.

Key Numbers

• 2023-12-31 — Fiscal Year End (Period covered by the 20-F filing)
• 2023-01-01 — Reporting Period Start (Period covered by the 20-F filing)
• 001-36187 — SEC File Number (Evogene's SEC file number)
• 0001574565 — Central Index Key (Evogene's Central Index Key)

Key Players & Entities

• Evogene Ltd. (company) — Filer of the 20-F report
• 20-F (filing) — Type of report filed
• December 31, 2023 (date) — Fiscal year end date
• January 1, 2023 (date) — Start of the reporting period
• 13 Gad Feinstein Street, Park Rehovot, Rehovot, Israel (address) — Company's business address
• 2870 (sic_code) — Standard Industrial Classification code for Agriculture Chemicals

FAQ

Industry Context

Evogene Ltd. operates within the agriculture chemicals industry, focusing on developing and commercializing innovative technologies for crop improvement.

Regulatory Implications

As a foreign private issuer, Evogene Ltd. files annual reports on Form 20-F with the SEC, adhering to specific disclosure requirements for non-US companies.

What Investors Should Do

1. Analyze the financial statements within the 20-F for revenue, expenses, and profitability trends.
2. Review the 'Risk Factors' section for potential challenges and uncertainties facing Evogene.
3. Examine management's discussion and analysis (MD&A) for insights into business strategy and outlook.

Key Dates

• 2024-03-28: Filing Date — Date the 20-F report was filed with the SEC
• 2023-12-31: Fiscal Year End — End date of the reporting period

Year-Over-Year Comparison

This filing is the annual 20-F report for the fiscal year ended December 31, 2023, providing updated information compared to previous filings.

Key Financial Figures

• $26.5 million — urred operating losses of approximately $26.5 million , $26.9 million and $31.0 million for t
• $26.9 million — losses of approximately $26.5 million , $26.9 million and $31.0 million for the years ended D
• $31.0 million — ately $26.5 million , $26.9 million and $31.0 million for the years ended December 31, 2023,

Filing Documents

• zk2431172.htm (20-F) — 4331KB
• exhibit_2-1.htm (EX-2.1) — 29KB
• exhibit_4-11.htm (EX-4.11) — 136KB
• exhibit_4-12.htm (EX-4.12) — 210KB
• exhibit_12-1.htm (EX-12.1) — 9KB
• exhibit_12-2.htm (EX-12.2) — 8KB
• exhibit_13-1.htm (EX-13.1) — 3KB
• exhibit_13-2.htm (EX-13.2) — 3KB
• exhibit_15-1.htm (EX-15.1) — 5KB
• exhibit_97-1.htm (EX-97.1) — 30KB
• image0.jpg (GRAPHIC) — 412KB
• image00003.jpg (GRAPHIC) — 66KB
• image00004.jpg (GRAPHIC) — 26KB
• image1.jpg (GRAPHIC) — 241KB
• 0001178913-24-001137.txt (&nbsp;) — 19375KB
• evgn-20231231.xsd (EX-101.SCH) — 142KB
• evgn-20231231_cal.xml (EX-101.CAL) — 82KB
• evgn-20231231_def.xml (EX-101.DEF) — 316KB
• evgn-20231231_lab.xml (EX-101.LAB) — 1019KB
• evgn-20231231_pre.xml (EX-101.PRE) — 517KB
• zk2431172_htm.xml (XML) — 4223KB

Quantitative and Qualitative Disclosures About Market Risk

Quantitative and Qualitative Disclosures About Market Risk 112 ITEM 12.

Description of Securities other than Equity Securities

Description of Securities other than Equity Securities 113 PART II ITEM 13. Defaults, Dividend Arrearages and Delinquencies 113 ITEM 14. Material Modifications to the Rights of Security Holders and Use of Proceeds 113 ITEM 15.

Controls and Procedures

Controls and Procedures 114 ITEM 16. [Reserved] 114 ITEM 16A. Audit Committee Financial Expert 114 ITEM 16B. Code of Ethics 115 ITEM 16C. Principal Accountant Fees and Services 115 ITEM 16D. Exemptions from the Listing Standards for Audit Committees 115 ITEM 16E. Purchases of Equity Securities by the Issuer and Affiliated Purchasers 115 ITEM 16F. Change in Registrant's Certifying Accountant 116 ITEM 16G. Corporate Governance 116 ITEM 16H. Mine Safety Disclosure 116 ITEM 16I. Disclosure Regarding Foreign Jurisdictions that Prevent Inspections 116 ITEM 16J. Insider Trading Plans 116 ITEM 16K. Cybersecurity 117 PART III ITEM 17.

Financial Statements

Financial Statements 117 ITEM 18.

Financial Statements

Financial Statements 117 ITEM 19. Exhibits 118

Signatures

Signatures 119 Index to Consolidated Financial Statements F-1 3 CERTAIN TERMS AND CONVENTIONS In this Annual Report, unless otherwise specifically stated or the context otherwise requires: references to "Evogene," "we," "us," "our," "our company" and "the company" refer to Evogene Ltd. and its consolidated subsidiaries, consisting of AgPlenus Ltd., or AgPlenus, Biomica Ltd., or Biomica, Canonic Ltd., or Canonic, Casterra Ag Ltd., or Casterra, Evogene Inc., Lavie Bio Ltd., or Lavie Bio, and their consolidated subsidiaries; references to "U.S. dollars," "USD," "$" or "dollars" are to United States dollars; references to "NIS" or "shekels" are to New Israeli Shekels; references to the "U.S." are to the United States; references to "ordinary shares," "our shares" and similar expressions refer to our Ordinary Shares, par value NIS 0.02 per share; references to the "articles of association" are to our Amended and Restated Articles of Association, which became effective upon the closing of the U.S. initial public offering, as subsequently amended; references to the "Companies Law" are to the Israeli Companies Law, 5759-1999, as amended; references to the "Securities Act" are to the Securities Act of 1933, as amended; references to the "Exchange Act" are to the Securities Exchange Act of 1934, as amended; references to the "NYSE" are to the New York Stock Exchange; references to the "Nasdaq" are to the Nasdaq Stock Market LLC or the Nasdaq Global Market; references to the "TASE" are to the Tel Aviv Stock Exchange; and references to the "SEC" are to the United States Securities and Exchange Commission. Unless derived from our financial statements or otherwise noted, amounts presented in this Annual Report are translated at the rate of NIS 3.627 = USD 1.00, the exchange rate between the NIS and the U.S. dollar reported by the Bank of Israel as of December 31, 2023. This Annual Report includes other statistical, market and industry data and forecasts wh

Risk Factors

Risk Factors Our business faces significant risks. You should carefully consider all of the information set forth in this Annual Report and in our other filings with the SEC, including the following risk factors which we face and which are faced by the industries in which we operate. Our business, financial condition or results of operations could be materially adversely affected by any of these risks. This report also contains forward-looking statements that involve risks and uncertainties. Our results could materially differ from those anticipated in those forward-looking statements, as a result of certain factors, including the risks described below and elsewhere in this report and our other SEC filings. See "Special Note Regarding Forward-Looking Statements" on page 5. Risks Related to Our Business and Industry We have a history of operating losses and negative cash flow, and we may never achieve or maintain profitability. We have a history of losses, and incurred operating losses of approximately $26.5 million , $26.9 million and $31.0 million for the years ended December 31, 2023, 2022 and 2021, respectively. There is no assurance that our efforts in developing our product candidates will result in commercially successful products. We expect to continue to incur losses in future periods, until we begin earning significant revenues or royalties on our products, the product candidates we are currently developing or any new product candidates we develop in the future, if at all. Because we will incur significant costs and expenses for these efforts before we obtain any incremental revenues from them, our losses in future periods could be significant. In addition, we may find that these efforts are more expensive than we anticipate or that they do not result in profitability in the time period we anticipate, which would further increase our losses. For example, if we are unable to adequately control the costs associated with operating our business, including

View Full Filing

View this 20-F filing on SEC EDGAR